These monoclonal antibodies, which are directed against members of the T cell immune pathway (PD-1, PD-L1 or CTLA-4), have shown promising therapeutical outcomes, with approval for more than 17 cancer entities in 2019 and more than 2250 active clinical trials in 2018 [2,3]. Here, CD274 is linked to cancer.